The HAX1 Knockout HeLa Polyclonal Cells product consists of a polyclonal population of HeLa cells engineered via CRISPR/Cas9-mediated disruption of the HAX1 gene. This loss-of-function model enables investigation of HAX1-dependent processes without clonal selection, preserving population-level heterogeneity while abolishing target protein expression across the culture. The polyclonal format is particularly suited for pooled functional screens and assays where diverse genetic backgrounds may reveal variable dependencies on HAX1 function.
The host cell line, HeLa, is a widely utilized epithelial carcinoma cell line derived from a human cervical adenocarcinoma. These cells exhibit robust proliferation and have been extensively characterized in cancer biology, providing a well-established platform for studying oncogenic signaling, apoptosis, and cell migration. Their ease of culture and transfection makes them ideal for CRISPR-based gene editing, and the resulting knockout cells retain the key characteristics of the parental line while lacking HAX1 activity.
HAX1 (HS1-associated protein X-1) is an anti-apoptotic protein localized to mitochondria and the endoplasmic reticulum. It interacts with BCL2 family members such as BCL2 and BCL-XL to maintain mitochondrial membrane integrity, thereby preventing cytochrome c release. HAX1 also directly binds and inhibits the serine protease HtrA2/Omi, further suppressing caspase-9 activation and downstream apoptosis. Beyond cell survival, HAX1 associates with cortactin (HCLS1) and vimentin to regulate actin dynamics and focal adhesion turnover, facilitating cell migration. Additionally, HAX1 modulates calcium homeostasis through interaction with polycystin-2 (PKD2), linking it to calcium signaling pathways. Transcription of HAX1 is controlled by SP1 and NF-Y, and its expression is induced by cytokines such as IL-3 and GM-CSF.
In the HeLa cervical cancer background, HAX1 knockout is particularly relevant due to the frequent overexpression of HAX1 in various tumors. This overexpression contributes to apoptotic resistance and enhanced migratory capacity, two hallmarks of malignancy. Disruption of HAX1 in HeLa cells provides a valuable model to dissect its role in mitochondrial integrity, calcium handling, and integrin-mediated adhesion within a cancer context. The knockout cells may exhibit increased sensitivity to apoptotic stimuli, altered migratory behavior, and changes in drug responsiveness, enabling detailed mechanistic studies.
Key research applications include apoptosis pathway analysis using Annexin V staining and JC-1 mitochondrial membrane potential assays, as well as caspase-3 and -9 activity measurements. Western blotting for HAX1, BCL2, and BAX verifies expression changes, while co-immunoprecipitation can probe interactions with BCL2 or cortactin. Immunofluorescence localizes HAX1 or its binding partners, and scratch wound migration assays quantify cell motility. RT-qPCR can confirm HAX1 transcript disruption. For further details or custom inquiries, please contact Ascent Research.
